Cargando…
Pre-clinical study of IRDye800CW-nimotuzumab formulation, stability, pharmacokinetics, and safety
BACKGROUND: Epidermal growth factor receptor (EGFR) is a target for cancer therapy as it is overexpressed in a wide variety of cancers. Therapeutic antibodies that bind EGFR are being evaluated in clinical trials as imaging agents for positron emission tomography and image-guided surgery. However, s...
Autores principales: | Bernhard, Wendy, Barreto, Kris, El-Sayed, Ayman, Gonzalez, Carolina, Viswas, Raja Solomon, Toledo, Darien, Casaco, Angel, DeCoteau, John, Fonge, Humphrey, Geyer, Clarence Ronald |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7953729/ https://www.ncbi.nlm.nih.gov/pubmed/33711962 http://dx.doi.org/10.1186/s12885-021-08003-3 |
Ejemplares similares
-
Near infrared fluorescence imaging of EGFR expression in vivo using IRDye800CW-nimotuzumab
por: Bernhard, Wendy, et al.
Publicado: (2017) -
(89)Zr-nimotuzumab for immunoPET imaging of epidermal growth factor receptor I
por: Chekol, Rufael, et al.
Publicado: (2018) -
Evaluation of nimotuzumab Fab(2) as an optical imaging agent in EGFR positive cancers
por: Bernhard, Wendy, et al.
Publicado: (2023) -
Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
por: Gao, Rebecca W., et al.
Publicado: (2018) -
Therapeutic potential of nimotuzumab PEGylated-maytansine antibody drug conjugates against EGFR positive xenograft
por: Hartimath, Siddesh V., et al.
Publicado: (2019)